Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

Abstract

Background: Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial. Objective: To evaluate long term efficacy and safety of adalimumab maintenance therapy in Crohn's disease in a follow-on randomised controlled trial (CLASSIC II).

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

“…Such patients may benefit from switching to an alternative anti-TNF treatment. Adalimumab, a fully human IgG1 antibody, was the second anti-TNF molecule to become commercially available for treatment of Crohn's disease 9,10 and has been shown to have efficacy in patients with loss of response, or intolerance, to infliximab.…”

Systematic review: steroid withdrawal in anti‐TNF‐treated patients with inflammatory bowel disease

“…Of these eight studies, seven were excluded for the following reasons (see online Supporting information): insufficient follow-up (5), [65][66][67][68][69] no clear distinction between UC and CD patients (1), 70 and no maintenance treatment (1). 71 After applying all inclusion and exclusion criteria, one study reporting on CD was included for the purpose of this review. 17 See for a detailed overview of this study Table 3.…”

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

“…It was also the first human antibody approved for use in inflammatory bowel disease. Clinical trials showed that adalimumab is effective for treating Crohn's disease and ulcerative colitis [44][45][46][47][48][49][50][51]. Similarly to infliximab, additional pharmacokinetic studies showed that antibodies to adalimumab predicted Crohn's disease recurrence [52].…”